Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, Masand P, Maris JM, Martinez D, Pogoriler J, Varadarajan N, Thakkar SG, Lyon D, Lapteva N, Mei Z, Patel K, Lopez-Terrada D, Ramos C, Lulla P, Armaghany T, Grilley BJ, Dotti G, Metelitsa LS, Heslop HE, Brenner MK, Sumazin P, Heczey A. Steffin D, et al. Among authors: lapteva n. Res Sq [Preprint]. 2024 Apr 3:rs.3.rs-4103623. doi: 10.21203/rs.3.rs-4103623/v1. Res Sq. 2024. PMID: 38645165 Free PMC article. Preprint.
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N. Hegde M, et al. Among authors: lapteva n. Nat Cancer. 2024 Apr 24. doi: 10.1038/s43018-024-00749-6. Online ahead of print. Nat Cancer. 2024. PMID: 38658775
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Lin FY, et al. Among authors: lapteva n. J Clin Oncol. 2024 May 21:JCO2302019. doi: 10.1200/JCO.23.02019. Online ahead of print. J Clin Oncol. 2024. PMID: 38771986
Visuo-spatial imagery in dreams of congenitally and early blind: a systematic review.
Ilic K, Bertani R, Lapteva N, Drakatos P, Delogu A, Raheel K, Soteriou M, Mutti C, Steier J, Carmichael DW, Goadsby PJ, Ockelford A, Rosenzweig I. Ilic K, et al. Among authors: lapteva n. Front Integr Neurosci. 2023 Jun 30;17:1204129. doi: 10.3389/fnint.2023.1204129. eCollection 2023. Front Integr Neurosci. 2023. PMID: 37457556 Free PMC article. Review.
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.
Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Vasileiou S, et al. Among authors: lapteva n. Haematologica. 2023 Jul 1;108(7):1840-1850. doi: 10.3324/haematol.2022.281946. Haematologica. 2023. PMID: 36373249 Free PMC article. Clinical Trial.
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Hoyos V, et al. Among authors: lapteva n. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221107113. doi: 10.1177/17588359221107113. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35860837 Free PMC article.
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Steffin DHM, et al. Among authors: lapteva n. Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728. Blood. 2022. PMID: 35325065 Free PMC article.
Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study.
Ibenana L, Anderson R, Gee A, Gilbert M, Cox C, Hare JM, Brooks A, Kelley L, Khan A, Lapteva N, Orozco A, Styers D, Sumstad D, Ugochi I, McKenna DH. Ibenana L, et al. Among authors: lapteva n. Cytotherapy. 2022 Jul;24(7):691-698. doi: 10.1016/j.jcyt.2022.01.010. Epub 2022 Mar 9. Cytotherapy. 2022. PMID: 35279374 Free PMC article.
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL.
Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Naik S, et al. Among authors: lapteva n. Blood. 2022 Apr 28;139(17):2706-2711. doi: 10.1182/blood.2021014648. Blood. 2022. PMID: 35134127 Free PMC article.
103 results